BlackfinBio Announces FDA Clearance to Initiate Phase 1/2 Clinical Trial for Novel AAV Gene Therapy BFB-101 to Treat the Rare Neurological Disease Hereditary Spastic Paraplegia, Type 47 (SPG47)
April 28, 2025 04:00 ET | Source: BlackfinBio CHESHIRE, United Kingdom, April…
NEXTGEN DIGITAL ANNOUNCES UPSIZE OF NON-BROKERED PRIVATE PLACEMENT TO $1.2 MILLION & PURCHASE OF XRP COINS
– NOT FOR DISSEMINATION IN THE UNITED STATES OR THROUGH U.S. NEWSWIRE…
Galapagos Announces Encouraging New Results from Ongoing Phase 1/2 Study of CD19 CAR T-Cell Therapy, GLPG5101, in Patients with Relapsed/Refractory Non-Hodgkin Lymphoma
Data from the ongoing Phase 1/2 ATALANTA-1 study in a heavily pretreated…
Roquette Successfully Completes Inaugural EUR 1.2 billion Bond Offering to Support its Transformative Acquisition of IFF Pharma Solutions
Roquette Successfully Completes Inaugural EUR 1.2 billion Bond Offering to Support its…